

Echo Hawaii 2020



No personal COI

#### **Institutional**

MedStar Health has Institutional contracts for my work as Director of an Academic Core Lab:

Abbott, Boston Scientific, Edwards, Medtronic, Neovasc, Livanova, GDS, Mitralign.

MedStar Health Research Institute

MedStar Health Research Institute









![](_page_3_Figure_1.jpeg)

## Background (i)

- Secondary or functional mitral regurgitation (SMR) is present in >50% of patients with heart failure (HF), and is severe in ~10-15%.
- Prognosis is poor when SMR is severe.
- Evaluation of SMR is challenging, due to asymmetric leaflet anatomy and regurgitant orifice, eccentric jets and enlarged left cardiac chambers.
- Expert panels have disagreed on how to define the severity of SMR, resulting in conflicting European and American guidelines.

![](_page_4_Figure_1.jpeg)

#### Why are the COAPT Results so Different from MITRA-FR? Possible Reasons

MITRA-FR (n=304)	COAPT (n=614)
Severe FMR by EU guidelines: EROA >20 mm <sup>2</sup> or RV >30 mL/beat	Severe FMR by US guidelines: MULTIPARAMETRIC EROA >30 mm <sup>2</sup> or PVSFR
31 ± 10 mm <sup>2</sup>	41 ± 15 mm <sup>2</sup>
135 ± 35 mL/m²	101 ± 34 mL/m <sup>2</sup>
Receiving HF meds at baseline – allowed variable adjustment in each group during follow-up per "real- world" practice	CEC confirmed pts were failing maximally-tolerated GDMT at baseline – few major changes during follow-up
9% / 9%	5% / 5%
14.6%	8.5%
17% Slide from GW Stone's LECT T	5% 57 2018
	MITRA-FR (n=304)Severe FMR by EU guidelines: EROA >20 mm² or RV >30 mL/beat $31 \pm 10 \text{ mm}^2$ $135 \pm 35 \text{ mL/m}^2$ Receiving HF meds at baseline – allowed variable adjustment in each group during follow-up per "real- world" practice $9\% / 9\%$ $14.6\%$ 14.6%

## SO... How did SMR patients qualify to COAPT?

- MR Severity
- MV Anatomy and other echo characteristics

![](_page_5_Picture_5.jpeg)

![](_page_6_Figure_1.jpeg)

![](_page_6_Picture_3.jpeg)

![](_page_7_Figure_1.jpeg)

![](_page_7_Figure_3.jpeg)

# Vena Contracta

![](_page_8_Picture_2.jpeg)

### VC width (cm)

Severe > 0.7

**COAPT** > 0.5

![](_page_8_Picture_7.jpeg)

![](_page_9_Figure_1.jpeg)

## MV Anatomy and other echo characteristics

![](_page_9_Figure_4.jpeg)

## MV Anatomy and other echo characteristics

![](_page_10_Picture_2.jpeg)

![](_page_10_Picture_4.jpeg)

![](_page_11_Figure_1.jpeg)

![](_page_11_Figure_3.jpeg)

![](_page_12_Figure_1.jpeg)

![](_page_12_Picture_3.jpeg)

![](_page_13_Picture_1.jpeg)

![](_page_13_Picture_3.jpeg)

![](_page_14_Figure_1.jpeg)

![](_page_14_Figure_2.jpeg)

![](_page_15_Picture_1.jpeg)

# 2. Clip positioning and alignment

![](_page_15_Picture_4.jpeg)

#### Steering and Positioning the MitraClip above the MV

![](_page_16_Figure_2.jpeg)

- Align clip perpendicular to plane of mitral annulus
- Align clip arms perpendicular to coaptation line
- Align clip parallel to antegrade flow
- Move in small iterations
- Center over origin of MR jet

Wunderlich and Siegel Eur Heart J: CV Imaging 2013;;14:935-949

![](_page_16_Figure_10.jpeg)

# 4. Verify residual MR is not >2+

![](_page_17_Picture_2.jpeg)

![](_page_17_Picture_4.jpeg)

![](_page_18_Picture_1.jpeg)

![](_page_18_Picture_3.jpeg)

![](_page_19_Figure_1.jpeg)